Abstract
Background: Breast cancer remains a major global health burden despite therapeutic advances, necessitating further innovations to address persistent challenges like therapeutic resistance, adverse effects, and mortality in subgroups. Emerging technologies offer promising opportunities in this regard through data-driven, precise, and personalized approaches.
Main body: Omics-guided therapies leverage genome, epigenome, and other profiling to enable better characterization of complex cancer molecular alterations driving selection and monitoring of tailored treatment regimens. Gut microbiome manipulation via probiotics, prebiotics or fecal transplantation aims to counter dysbiosis linked to breast cancer progression. Nanotechnology-engineered platforms offer smart drug delivery selectively to tumors and integrated diagnostic-therapeutic functions. Artificial intelligence algorithms analyze complex datasets and images to extract detailed quantitative signatures guiding prognostic decisions and personalized care. Traditional Chinese medicine encompassing herbal remedies and acupuncture demonstrates anticancer effects in preclinical models, with early trials exploring integration with chemotherapy.
Conclusion: Substantial progress has been made in breast cancer management, yet significant unmet needs persist. Emerging modalities have shown tremendous translational potential through molecularly targeted, immunomodulatory, data-driven approaches improving upon conventional methods regarding precision, effectiveness, and quality of life. Incremental integration of these innovative technologies promises to transform breast cancer care.
Keywords
Breast cancer, Precision oncology, Omics microbiome, Nanotechnology, Artificial intelligence, Traditional Chinese medicine